Clinical Trial Update: A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises [Phase 3]

View source ↗

Summary

Pfizer's inclacumab in sickle cell disease patients experiencing vaso-occlusive crises has completed Phase 3 testing. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Inclacumab

Snippet

Sponsor: Pfizer | Conditions: Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease | Phase 3 | Status: COMPLETED | Results posted: 2025-12-02